Ra Capital Management, L.p. bought $54M of JANX
director, owner at Janux Therapeutics, Inc.. 1,200,000 shares at an average of $44.75, traded Oct 18, 2024, filed Oct 22, 2024.
Score components
- +15RoleDirector
- +25Trade size$53.7M at market
- +3Relative to holdingsHoldings up 15%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.9%, 3m -22.5%, 6m -43.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025502, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | POpen-market purchase Common Stockindirect: See footnotes | +1,200,000 | $44.75 | $54M | 9,317,246 | Oct 22, 2024 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25M 824,041 shares | +9% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,334 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 29Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $732k 13,334 shares | -14% | |
| 43Moderate | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.4M 25,000 shares | -10% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.0M 15,000 shares | -6% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -9% | |
| 38Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -8% | |
| 19Weak | JANXsell Janux Therapeutics, Inc. | Jay Lichter owner | $178k 3,815 shares | -35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.